PMS9 TREATING ARTHRITIS OF THE KNEE: THE IMPACT ON PAIN IN PATIENTS' EVERYDAY LIVES
Taieb C Pierre Fabre, Boulogne, France Arthritis of the knee is a real public health problem. Its prevalence is estimated at 6.1% of adults aged over 30 years, according to data from the Framingham Study. OBJECTIVES: To observe, in real use conditions, the effects obtained by Hyaluronic acid in the treatment of arthritis of the knee combined with a prescription of Sodium chondroitine sulfate between 2 treatments. METHODS: A longitudinal, prospective observation programme. RESULTS: Forty-two patients were treated with Hyaluronic acid and Soduium chondroitine sulfate , 19 patients were treated on the left side of the knee and 22 on the right side, with hyaluronic acid. At inclusion, average pain during daily life activities was 53,289 20,836, at W18, 37,963 17,173 and at M6, 35,625 17,956 . Development of the pain during daily life activities between inclusion and W18 was signifi cant (p 0.0056) as was the same between inclusion and M6 (p 0.0011). At inclusion, average pain at rest was 29,167 16,889, at W18, 19,792 14,255 and at M6, 19,217 17,399 . Development of pain at rest between inclusion and W18 was not signifi cant (p 0.0594) (however the p-value was very close to 0.05 . . .) as was the same between inclusion and M6 (p 0.0619). CONCLUSIONS: The reduction of the pain -which was signifi cant during patients' daily activities at 18 weeks, and then sustained at 6 months -is a testimony to the relevance of this treatment protocol. A greater number of trial subjects would make it possible to confi rm the signifi cance of the reduction of pain at rest.
PMS10 DOSING PATTERNS FOR RHEUMATOID ARTHRITIS PATIENTS T REATED WITH ABATACEPT OR INFLIXIMAB
Trivedi DN 1 , Chapman RH 2 , Smith D 2 , Semroc G 2 , Rosenblatt LC 1 1 Bristol-Myers Squibb, Plainsboro, NJ, USA, 2 IMS Health, Falls Church, VA, USA OBJECTIVES: To determine dosing patterns associated with real-world treatment of rheumatoid arthritis (RA) patients with infl iximab or abatacept. METHODS: An observational, retrospective (cohort) study of patients new to abatacept and infl iximab was conducted using the PharMetrics Patient-Centric Database. All adult patients with at least one claim of RA diagnosis at or prior to initial treatment with infl iximab or abatacept from March 2006 to June 2007 were selected. Patients were identifi ed and followed for at least 6 months based on their fi rst infusion claim for infl iximab or abatacept with no claims for any other biologic in the prior 6 months. Abatacept and infl iximab cohorts were compared with respect to baseline characteristics and occurrence of upward dose adjustments (increase in dose or frequency). RESULTS: Forty abatacept and 216 infl iximab patients were identifi ed as new to biologic therapy. The two cohorts were generally similar, however 47.5% of initial infusions for abatacept patients were prescribed by a rheumatologist (also, 15% by primary care physician (PCP) and 37.5% unknown), compared to 72.7% for infl iximab patients (with 4.6% by PCP and 22.6% unknown). Abatacept patients were less likely to experience upward dose adjustment than infl iximab (10% vs. 57.9%, respectively). Multivariable Cox proportional hazards modeling (adjusted for age, gender, Charlson Comorbidity Index, and 1-year pre-index RA-related costs) determined that infl iximab patients were more likely to experience upward dose adjustment than abatacept patients (HR 5.5, 95% confi dence interval 2.0-14.9, p 0.001). CONCLUSIONS: Upward dose adjustment with some biologic therapies is common and may lead to unexpectedly higher treatment costs with additional safety considerations. In this study, upward dose adjustment appears to be less likely in patients started on abatacept than infl iximab. Further research should determine if the fi xed dosing pattern observed with abatacept continues over time, as health care providers and patients become more familiar with this biologic.
PMS11 RELATIONSHIP BETWEEN LEVELS OF PHYSICAL ACTIVITY AT WORK AND PREVALENCE OF ARTHRITIS AMONG WORKING POPULATION
Bali V, Khan N V V University of New Mexico, Albuquerque, NM, USA OBJECTIVES: Arthritis is the most common chronic illness in the US. Various studies have found association between arthritis and physical demands of work. This study determines the relationship between physical activity at work and prevalence of arthritis among working population. METHODS: To distinguish between arthritic and non arthritic population we used question from the 2007 Behavioral Risk Factor Surveillance System (BRFSS) that indicates whether an individual was suffering from arthritis that had been diagnosed by physician. We also determined an individual level of physical activity at work through the question that classifi es an individual level of physical activity at work into three levels. RESULTS: The sample consists of 205,533 respondents out of which (46, 078) 22.42% had arthritis and (15, 9455) 77.58% did not have any type of arthritis. Results from the logistic regression showed signifi cant relationship between prevalence of arthritis and gender, age, race, education, income, reported health status, BMI, health coverage and physical activity at work ( 0.05). There was inconsistent relationship among the level of physical activity and prevalence of arthritis as people having moderate physical activity had lesser odds (O.R. 0.965, 95% CI: 0.938-0.994) of suffering from arthritis i.e. one unit increase in moderate physical activity at work was associated with 3.5% decrease in the odds of suffering from arthritis. However, people having heavy physical activity at work had greater odds of (O.R. 1.265, 95% CI: 1.220-1.311) of suffering from arthritis indicating that one unit increase in heavy physical activity was associated with 27% increase in the odds of suffering from arthritis. CONCLUSIONS: There is a need to investigate in greater detail the role of physical activity at work in conjunction with other factors on the prevalence of arthritis. This investigation can help in identifying people susceptible to develop arthritis along with the factors responsible for their illness.
PMS12
FIBROMYALGIA: RUSSIAN RHEUMATOLOGISTS' KNOWLEDGE Nasonov E 1 , Le Lay K 2 , Soldatov D 3 , Taieb C 2 1 Rheumatology Institute-Russian Federation, Moscou, Russia, 2 Pierre Fabre, Boulogne, France, 3 Pierre Fabre Laboratories, Moscou, Russia CONTEXT: Fibromyalgia syndrome (FMS) is an under-diagnosed. OBJECTIVES: To describe Russian rheumatologists' knowledge of fi bromyalgic patients. METHODS: The questionnaire was sent to a random sample of Russian practitioners, who were answering the same questionnaire as that used by French practitioners in 2003.
RESULTS:
The average number of patients seen daily by each practitioner was 58 (median 36 patients) 88% and 75% of the doctors claimed, individually, that they had not received any education on fi bromyalgia or chronic fatigue during their medical studies. During their professional activity, 53.9% of the doctors have still not had any professional training on fi bromyalgia. One percent of the doctors believed that fi bromyalgia does not exist, while 36.5% believed that fi bromyalgia is an illness and 63.2% that it is a syndrome. Forty percent of the doctors who answered were continuing to treat fi bromyalgic patients, 28% referred them to a specialist rheumatologist, 14% to a neurologist and 9% to a psychiatrist. Excessive fatigue, diffuse pain, a tendency to feel depressed, anxious and sad, and muscle weakness were recognised respectively as being the main symptoms of fi bromyalgia by 64, 77, 64 and 45 % of the rheumatologists respectively. Digestive problems, palpitations, swollen joints and radiological irregularities were recognised as being the main symptoms of fi bromyalgia by 10, 13, 12 and 9% of the rheumatologists respectively. CONCLUSIONS: As in EC countries, a wide-scale training effort should be made in order to improve the diagnosing of patients. The data collected via these evaluations was close to the results for France.
